FDA inspection
Fresenius Kabi Norge As: FDA inspection ending Nov 9, 2007
FDA inspection 499342 · No Action Indicated (NAI) · Halden
Key facts
| Inspection ID | 499342 |
|---|---|
| Firm | Fresenius Kabi Norge As |
| FEI number | 3002608066 |
| Address | Svinesundsveien 80 |
| City | Halden |
| Fiscal year | 2008 |
| Inspection end date | Nov 9, 2007 |
| Classification | No Action Indicated (NAI) |
| Project area | Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood & Blood Products|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance|Blood and Blood Products|Drug Quality Assurance |
| Product type | Biologics, Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data